ALISON CRAWFORD,ERIC SMITH,FRANK DELFINO,JESSICA R. KIRSHNER,JOHN RUDGE,LAURIC HABER,THOMAS NITTOLI
申请号：
BR112019005641
公开号：
BR112019005641A2
申请日:
2017.09.22
申请国别(地区):
BR
年份:
2019
代理人:
摘要：
The protein known as the prostate transmembrane epithelial antigen 6 (steap2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides full length human IgG antibodies that bind to human steap2 (monospecific antibodies). the present invention: (i) provides bispecific antibodies (bsabs) that bind to both steap2 and cd3 and activate t cells via the cd3 complex in the presence of steap2 expressing tumors； (ii) provides bispecific antigen binding molecules comprising first antigen binding domain specifically binding to human and monkey cd3 and second antigen binding molecule specifically binding human steap2； (iii) includes drug steap2 antibody conjugates that inhibit tumor growth in vivo. the bispecific antigen binding molecules of the present invention are capable of inhibiting tumor growth expressing steap2. The bispecific antigen-binding molecules of the invention are useful for treating prostate diseases and disorders in which over-regulated or induced steap2-directed immune response is desired and / or therapeutically beneficial. For example, bispecific antibodies of the invention are useful for treating prostate cancers, including castration resistant prostate cancer.a proteína conhecida como antígeno epitelial transmembrana seis da próstata 2 (steap2) é altamente expressa no câncer da próstata e está associada à expressão de outros genes associados ao câncer da próstata. a presente invenção proporciona anticorpos de igg humana de comprimento total que ligam a steap2 humano (anticorpos monoespecíficos). a presente invenção: (i) proporciona anticorpos biespecíficos (bsabs) que ligam tanto steap2 quanto cd3 e ativam células t via complexo de cd3 na presença de tumores expressando steap2； (ii) proporciona moléculas de ligação ao antígeno biespecíficas compreendendo primeiro domínio de ligação ao antígeno que liga especificamente cd3 humana e de macaco e segunda molécula de
